Literature DB >> 20622492

Comparative proteomic analysis of human amniotic fluid supernatants with Down syndrome using mass spectrometry.

Jisook Park1, Dong-Hyun Cha, Jin Woo Jung, Young Hwan Kim, Sook Hwan Lee, Youngjun Kim, Kwang Pyo Kim.   

Abstract

Down syndrome (DS) is an abnormality of the 21st chromosome that commonly occurs in children born to advanced age women. Amniotic fluid (AF) is usually collected from such women for prenatal diagnosis. This study analyzed human AF supernatants (AFS) by mass spectrometric (MS) approach to search for candidate biomarkers of DS pregnancy. AFS were collected from advanced age pregnant women at 16-18th weeks of gestation by amniocentesis for cytogenetic analysis. AFS from pregnancies carrying DS (n=4) or chromosomally normal (n=6) fetuses, as revealed by cytogenetic analysis, were then subjected to global protein profiling by liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS). Affinity chromatography was applied prior to LC-ESI-MS/MS to minimize the masking effect of highly abundant albumin and immunoglobulin and thereby, increased the diversity of identified proteins. Hereby, at least 30 AFS proteins were newly identified and 44 AFS proteins were found to be differentially expressed between DS and normal cases. Six of these proteins were unique to DS cases while 11 proteins were unique to chromosomally normal cases. In addition, 19 AFS proteins were down-regulated and 8 were up-regulated in DS cases with varying fold changes. A western blot analysis confirmed the LC-ESI-MS/MS data that combined detection of Apolipoprotein A-II (apo A-II) and alpha-fetoprotein (AFP) could be a potential tool for diagnosing DS cases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20622492     DOI: 10.4014/jmb.0912.12035

Source DB:  PubMed          Journal:  J Microbiol Biotechnol        ISSN: 1017-7825            Impact factor:   2.351


  7 in total

Review 1.  Apolipoprotein A-I: insights from redox proteomics for its role in neurodegeneration.

Authors:  Jeriel T R Keeney; Aaron M Swomley; Sarah Förster; Jessica L Harris; Rukhsana Sultana; D Allan Butterfield
Journal:  Proteomics Clin Appl       Date:  2013-01       Impact factor: 3.494

Review 2.  Disturbance of redox homeostasis in Down Syndrome: Role of iron dysmetabolism.

Authors:  Eugenio Barone; Andrea Arena; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Free Radic Biol Med       Date:  2017-07-10       Impact factor: 7.376

Review 3.  Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics.

Authors:  Marzia Perluigi; Fabio Di Domenico; D Allan Buttterfield
Journal:  Proteomics Clin Appl       Date:  2014-02       Impact factor: 3.494

4.  2D DIGE analysis of maternal plasma for potential biomarkers of Down Syndrome.

Authors:  Wendy E Heywood; Tracey E Madgett; Darrell Wang; Amanda Wallington; Julie Hogg; Kevin Mills; Neil D Avent
Journal:  Proteome Sci       Date:  2011-09-19       Impact factor: 2.480

5.  Human coelomic fluid investigation: A MS-based analytical approach to prenatal screening.

Authors:  Donatella Aiello; Antonino Giambona; Filippo Leto; Cristina Passarello; Gianfranca Damiani; Aurelio Maggio; Carlo Siciliano; Anna Napoli
Journal:  Sci Rep       Date:  2018-07-20       Impact factor: 4.379

6.  IgGFc-binding protein in pregnancies complicated by spontaneous preterm delivery: a retrospective cohort study.

Authors:  Jaroslav Stranik; Marian Kacerovsky; Ondrej Soucek; Martina Kolackova; Ivana Musilova; Lenka Pliskova; Radka Bolehovska; Pavel Bostik; Jana Matulova; Bo Jacobsson; Ctirad Andrys
Journal:  Sci Rep       Date:  2021-03-17       Impact factor: 4.379

7.  Application of proteomics for the identification of biomarkers in amniotic fluid: are we ready to provide a reliable prediction?

Authors:  George Th Tsangaris; Athanasios K Anagnostopoulos; Georgia Tounta; Aris Antsaklis; Ariadni Mavrou; Aggeliki Kolialexi
Journal:  EPMA J       Date:  2011-06-19       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.